Online inquiry

IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5428MR)

This product GTTS-WQ5428MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD74 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001025158.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 972
UniProt ID P04233
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ5428MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4346MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ5864MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ4558MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ13579MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ6685MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ2783MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ2412MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ5145MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CAN-04
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW